ArticleJournal of clinical medicine2022

The Outcome of Discontinuing Tyrosine Kinase Inhibitors in Advanced Sarcoma Following a Favorable Tumor Response to Antiangiogenics Therapy.

Zhusheng Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.